2	Respiratory syncytial virus-specific immunoglobulin G (IgG)
3	concentrations associate with environmental and genetic factors: the
4	Factors Influencing Pediatric Asthma Study.
5	
6	Esther Erdei ^{1¶} , Dara Torgerson ^{2,3¶} , Rae O'Leary ⁴ , Melissa Spear ^{2,3} , Matias Shedden ¹ ,
7	Marcia O'Leary ⁴ , Kendra Enright ⁴ , Lyle Best ^{4, 5}
8	
9 10	¹ University of New Mexico Health Sciences Center College of Pharmacy, Albuquerque, NM, USA
11 12	² Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA
13	³ Department of Human Genetics, McGill University, Montreal, QC, Canada
14	⁴ Missouri Breaks Industries Research Inc, Eagle Butte, SD, USA
15	⁵ Turtle Mountain Community College, Belcourt, ND, USA
16	
17	
18	* Corresponding author
19	E-mail: lbest@restel.com (LGB)
20	
21	[¶] These authors contributed equally to this work.
22	

23 Abstract

Exposure to respiratory syncytial virus (RSV) during childhood is nearly ubiquitous by 24 age two, and infants who develop severe RSV bronchiolitis are more likely to develop 25 asthma later in life. In the Factors Influencing Pediatric Asthma (FIPA) study including 26 319 children from a Northern Plains American Indian community, we found 73% of 27 children to have high concentrations of RSV-specific IgG (>40 IU/mL). High 28 29 concentration of RSV-specific IgG was associated with increased exposure to secondhand tobacco smoke ($p=7.5x10^{-4}$), larger household size ($p=4.0x10^{-3}$), and lower levels 30 of total serum IgE (p=5.1x10⁻³). Parents of children with asthma more often reported an 31 32 RSV diagnosis and/or hospitalization due to RSV, and children with asthma had lower concentrations of RSV IgG as compared to those without asthma among RSV-exposed 33 individuals (mean 117 IU/mL vs. 154, p=7.1x10⁻⁴). However, lower RSV IgG was 34 surprisingly exclusive to children with asthma recruited during the winter months when 35 RSV is thought to circulate more broadly. Multivariate regression indicated the strongest 36 predictors of RSV-specific IgG concentration included asthma status (p=0.040), per cent 37 eosinophils (p=0.035), and an asthma x RSV season interaction ($p=3.7 \times 10^{-3}$). Among 38 candidate genes, we identified a genetic association between an intronic variant in 39 IFNL4 and RSV-specific IgG concentration whereby the minor allele (A) was associated 40 with higher concentration (rs12979860, p=4.3x10⁻³). Overall our findings suggest there 41 are seasonal differences in immunological response to RSV infection in asthma cases 42 vs. controls, and identify both environmental and genetic contributions that warrant 43 further investigation. 44

45 Introduction

Respiratory syncytial virus (RSV) is an RNA virus, classified as a member of the 46 Paramyxoviridae family of negative-strand RNA viruses in the order Mononegavirales. It 47 48 is the most common cause of bronchiolitis in infants during the first 2-3 years of life [1]. Infection by the human RSV orthopneumovirus is ubiquitous, affecting nearly all children 49 by two years of age worldwide [1]. The incidence of hospitalization for bronchiolitis in 50 51 European and American populations is about 30 per 1,000 in the first year of life [2,3]. Ethnic differences in incidence are noted in the United States, with increased risk 52 among Hispanic and American Indian populations [4,5]. Severe RSV infection as an 53 infant confers increased susceptibility to asthma [6-8] and perhaps atopy [6], within at 54 least the subsequent two decades of life. There is also evidence of impaired lung 55 function among young adults with viral bronchiolitis as infants [9]. Almost all infectious 56 agents are involved in complex interactions within their host, and this seems especially 57 true for RSV infection and sequelae. There is evidence that host genetic factors 58 influence the initial pathogenesis of RSV infection [10–13], and that the development of 59 asthma following severe RSV infection is likely due to both genetic [11] and 60 environmental [14] contributions. However, the relationship between immunological 61 62 response to RSV infection and asthma remains largely unexplored.

In spite of pervasive childhood infection and persisting IgG antibodies to RSV in adulthood [15,16], recurrent RSV infection among adults is relatively common [17–19] and a cause of significant morbidity [20,21]. In Tribal community settings, where multigenerational households are common, understanding RSV infection burden from infancy to adulthood is especially important to design preventions and protect

68	community health. The Factors Influencing Pediatric Asthma (FIPA) study [22] enrolled
69	324 children from a Northern Plains American Indian community to characterize the
70	environmental, social and genetic factors associated with asthma in this high-risk, high-
71	prevalence community. The goal of the present analysis was to quantify the
72	immunoglobulin G response to RSV infection in American Indian children with and
73	without asthma, and to investigate the environmental, clinical, and genetic factors that
74	associate with varying response.

75

76 Methods

77

78 Ethics approval and consent to participate

The research protocol was approved by the institutional review boards at the Collaborative Research Center for American Indian Health, Sanford Research, Sioux Falls, SD; the Great Plains Indian Health Service IRB, Aberdeen, SD and the local Tribal government. All participants' parents gave informed consent in writing and all children provided assent.

84

Study population

The Factors Influencing Pediatric Asthma (FIPA) study, enrolled 324 participants from a single site in a population-based, case/control study as previously described [22],

of which 319 were included in the current study. Briefly, 108 asthma cases were 88 ascertained by a global search of Indian Health Service electronic medical records for a 89 90 diagnosis related to asthma (ICD codes 493.00 through 493.92, plus 786.07 [wheezing] and V17.5 [family history of asthma]), and more specifically defined by at least 2 of 3 91 potential criteria (asthma diagnosis, at least 2 prescriptions for bronchodilator 92 medications within the past 2 years, or pulmonary function testing showing a 20% 93 improvement in FEV1 post bronchodilator treatment). Participating children were 94 between 6 and 17 years of age, and two asthma controls were recruited for every 95 asthma case. Cases were individually age-matched (within 6 months, N=216) to control 96 children who did not meet case criteria, primarily by a similar search of electronic 97 medical records. 98

Of 319 participants, 15 indicated their child was born prior to 36 weeks 99 gestational age including 6 asthma cases and 9 asthma controls (minimum reported 100 gestational age of 32 weeks, ranging from 32 – 35 weeks). Palivizumab may in some 101 102 cases be administered in the NICU to infants born prematurely to provide immunoprophylaxis against RSV, which may alter immunological response to RSV 103 104 infection. However, we were unable to guery NICU records to obtain this information, and parents were not specifically asked whether their child had ever received 105 Palivizumab in infancy. 106

107 Study procedures

Parents of potential participants were contacted by study field assistants via
 telephone and invited to participate if eligibility criteria were met. Parents of all

participants completed a standardized questionnaire related to socio-demographic. 110 housing environment and health history of their children. Two questions related to prior 111 RSV infections were asked, including "Has a medical person ever said that your child 112 had RSV? Yes or No.", and "Has your child ever had to stay overnight in the hospital? 113 Yes or No.". If they responded yes to prior hospitalization, parents were asked to fill in 114 115 the "Reason/Diagnosis", and "Age". From these questions, we generated two variables related to clinical manifestation of RSV infection, including self-reported "RSV infection" 116 and "RSV hospitalization". 117

At baseline, all children were examined for anthropometric measures, pulmonary 118 function testing, and home environmental sampling. The following laboratory samples 119 were obtained: (1) Blood was collected to perform basic measures of immune status 120 including % eosinophils, RSV IgG, total serum IgE, and C-reactive protein (CRP), 2) 121 salivary DNA samples (Oragene OGR-500, DNA Genotek, Ottawa, Canada) were 122 collected for DNA genotyping, following manufacturer approved extraction, and (3) 123 124 salivary cotinine samples (Accutest, NicAlert, Encino, California) were collected to measure exposure to tobacco products in the past 48 hours. A follow-up exam 125 approximately 3 years later, repeated pulmonary function testing and collected 126 additional biological samples for ancillary testing as described above. 127

128

129 Laboratory measurements

130 **RSV-specific IgG serum antibody concentrations** were determined
 131 on 319 participants, using stored serum collected at either baseline (1st exam, or study

entry, N=48) or at follow-up (2nd exam, N=271). RSV IgG serum concentration was 132 quantified using an IBL International certified sandwich ELISA assay (Hamburg, 133 Germany, catalogue number: RE RE56881-10, Lot#: RG-204). Each serum sample 134 was diluted 1:100 times before use, and 100 µL of each Standard solution (A-D) and 135 diluted sample were added to the RSV antigen pre-coated wells of the microtiter plate. 136 The process followed the protocol provided by the company and quality control 137 standards were included and assured at each run. Optical density (OD) was measured 138 with a spectrophotometer at 450 nm (Reference-wavelength: 600-650 nm) within 60 min 139 after pipetting of the stop solution. Standard curve point-to-point analysis method was 140 applied for each plate and run to determine RSV-specific IgG concentrations (IU/mI) for 141 each participant's serum sample. 142

Measurement of high sensitivity C-reactive protein (CRP) in serum
was done at Sanford Laboratories, Rapid City, SD, using a particle enhanced
immunoturbidimetric assay (Roche dedicated CRPHS reagent, catalog number
04628918190, Roche Diagnostics, Indianapolis, IN), on a Roche Cobas 6000
instrument using the manufacturer's recommended protocols.

Total IgE_determinations were also carried out by Sanford Laboratories, (Sioux
 Falls, SD) using fluorescent enzyme immunoassays for each antigen, (ImmunoCAP
 dedicated reagents, catalog number 10-9319-01, Phadia AB, Uppsala, Sweden) on the
 Phadia ImmunoCAP 250 instrument.

Complete blood count, including eosinophil and other specific cells, was
 measured on a SYSMEX XNL-450 hematology analyzer (Lincolnshire, IL) at the local

hospital within hours of phlebotomy, using reagents and quality controls as specified bythe manufacturer.

Salivary cotinine measures were obtained using the Accutest NicAlert[™]
 (Jant Pharmacal Corp, Encino, CA) with visual comparison to a standard strip resulting
 in 0-7 ordinal levels.

Genome-wide SNP genotyping was performed for 2.5 million variants on
 the expanded multi-ethnic genotyping array (MEGA^{EX} array, Illumina Inc.), with standard
 variant calling and quality control measures applied (genotyping rate > 95%, Hardy Weinberg p>0.0001, tests for unexpected relatedness/duplication between samples).
 The present study examined 11 selected variants related to clinical RSV outcomes.
 These additional measures were consistent with the participants' consents and
 approved by Tribal authorities.

166

167 **Statistical analysis**

168 Statistical analyses were performed using R [23]. Contrasts of the clinical 169 characteristics of asthma cases vs. controls, study participants with high IgG (>40 IU/mI) 170 vs. low/undetected IgG (<40 IU/mI), and individuals with asthma reporting asthma 171 medication usage were performed using a student's t-test. Multi-variable linear 172 regression was used to evaluate the correlation between serum RSV- specific IgG 173 concentrations (IU/mI) and asthma, household size at study entry, body mass index

(BMI), gender, acute exposure to tobacco (using saliva cotinine determinations), serum
 concentration of CRP, age, total IgE, and % eosinophils in whole blood.

The effect of seasonality on RSV-specific IgG concentration was also evaluated 176 by generating a binary variable for serum samples collected during periods of potentially 177 higher RSV transmission (December – April) vs. lower RSV transmission (May – 178 November), at either the baseline or follow-up visit. Tests of genetic association with 11 179 candidate variants selected from the literature potentially associated with RSV immune 180 or clinical response were performed using linear regression, adjusting for asthma, age, 181 and sex. Values of RSV-specific IgG concentration that were below assay detection 182 (left-censored) were transformed using $1/\sqrt{2}$ (N=11 samples) prior to association testing. 183

184

185 Results

186

Quantitative measurements of serum RSV IgG were obtained among 108 187 individuals with asthma, and 211 individuals without asthma (total N = 319). Clinical and 188 demographic characteristics of asthma cases and controls are summarized in Table 1. 189 At study entry, mean age, % male gender, and levels of C-reactive protein (CRP) were 190 not significantly different between asthma cases and controls. However, individuals with 191 asthma had a significantly smaller household size at baseline as compared to asthma 192 controls. (Table 1; p=1.6x10⁻⁴). Asthma cases also had higher levels of total serum IgE 193 as compared to asthma controls (Table 1, $p=3.1\times10^{-5}$), and a non-significant trend 194

- towards having higher BMI (p=0.054). The geometric mean of total IgE was 111 and
- 196 53% of children were above the clinical upper limit of normal (100 kU/L).

197

- 198 Table 1. Clinical characteristics of asthma cases and controls with measured
- 199 serum RSV IgG in the Factors Influencing Pediatric Asthma study (FIPA).

	Asthma	Asthma	P-value
	Cases	Controls	
Ν	108	211	-
Age at Enrollment (mean)	11.8	12.2	0.32
Gender (% male)	52.8	50.7	0.81
BMI (mean)	25.4	23.7	0.054
Cotinine (NicAlert, mean)	0.99	1.17	0.098
Household Size at Enrollment (mean)	5.3	6.3	1.6x10 ^{-4a}
Undetected (IgG<10 IU/mL, N)	0	26	1.6x10 ^{-5a}
High IgG (IgG > 40 IU/mL, %)	61.1	80.6	2.6x10 ^{-4a}
RSV IgG (IU/mL, mean)	117	135	0.093
RSV IgG (IU/mL, mean, excluding	117	154	7.1x10 ^{-4a}
undetected)			
Hospitalizations from RSV (%)	17.6%	6.7%	0.00358 ^a
RSV diagnosis (%)	34.6%	16.1%	4.5x10 ^{-4a}
Total Serum IgE [log (kU/L), mean]	5.2	4.4	3.1x10 ^{-5a}
% Eosinophils (mean)	5.0	3.8	0.0098
CRP (log, mean)	0.16	0.0050	0.22

^aStatistically significant following Bonferroni adjustment for 14 tests (p < 3.66x10⁻³).

202	The majority of individuals were classified as having high RSV-specific IgG
203	concentrations (N=236, or 73%), which was defined as being above 40 IU/ml threshold
204	by validation against the WHO standard per company protocol. A total of 26 individuals
205	had RSV-specific IgG concentrations < 10 IU/ml, indicating either no prior
206	infection/exposure to RSV or an impaired humoral response. All of these individuals
207	were asthma controls. To confirm the quality of the 26 serum samples where no or low
208	RSV IgG levels were detected, we measured vaccination-induced IgG concentrations

209	against measles, pertussis, and tetanus antigens (IBL International detection kits used).
210	All samples had measurable concentrations expressed as IU/ml values, providing
211	additional evidence these samples were of high quality and reflect reliable measures of
212	no/low RSV-specific IgG. Furthermore, we found vaccine-induced IgG concentrations
213	were not significantly different in individuals with low/no RSV IgG as compared to 17
214	individuals with RSV IgG concentrations > 10 IU/mI (S1 Fig). Characteristics of
215	individuals with high as compared to low concentration of RSV-specific IgG are
216	presented in Table 2, which include higher levels of cotinine (p=8.6x10 ⁻⁴), larger
217	household sizes at enrollment ($p=4.0x10^{-3}$), and lower levels of total serum IgE
218	(p=5.1x10 ⁻³).

219

Table 2. Comparison of individuals with high RSV IgG (>40 IU/ml vs. low (<40
 IU/ml).

	High IgG	Low IgG	P-value
Ν	236	83	-
Age at Enrollment (mean)	12.1	11.8	0.38
Gender (% male)	50.4	54.2	0.61
BMI (mean)	24.1	24.7	0.46
Cotinine (NicAlert, mean)	1.20	0.855	7.5x10 ^{-4a}
Household Size at Enrollment	6.2	5.4	4.0x10 ^{-3a}
(mean)			
Total Serum IgE [log (kU/L), mean]	4.57	5.12	5.1x10 ^{-3a}
CRP (log, mean)	0.33	0.27	0.65

^aStatistically significant following Bonferroni correction for 7 tests (p<7.1x10⁻³)

223

In our contrasts of individual variables, we found asthma cases had significantly lower serum RSV-specific IgG concentrations as compared to asthma controls among exposed individuals ($p=7.1x10^{-4}$, Table 1). Parents/guardians of asthma cases were

more likely to report their child had been previously diagnosed with RSV by a healthcare professional as compared to parents/guardians of asthma controls (34.6% vs. 16.1% respectively, p=4.5x10⁻⁴), more likely to report hospitalization due to RSV infection (17.6% for asthma cases vs. 6.7% for asthma controls, p=0.0036).

Asthma cases recruited during typical RSV season (December - April) had 231 significantly lower total RSV-specific IgG as compared to asthma cases recruited 232 233 outside of RSV season (May – November), and as compared to asthma controls regardless of RSV season (Fig 1). However, apart from RSV-specific IgG 234 concentrations, we found no differences in the clinical and demographic variables 235 between asthma cases recruited during vs. outside of RSV season (Table 3). In 236 contrast, asthma controls had similar levels of RSV IgG irrespective of the season they 237 were recruited in. In our multi-variate regression model, variables that were associated 238 with RSV-specific IgG were limited to asthma, % of blood eosinophils, and the 239 interaction between asthma x RSV season (Table 4). 240

241

Figure 1. Boxplot showing the distribution of serum RSV IgG in asthma cases vs.
controls, stratified by RSV season. Asthma cases recruited during RSV season
(Dec – April) have significantly lower RSV IgG as compared to asthma cases
recruited outside RSV season (May – Nov) (t-test, p=2.5x10⁻⁶). There was no
observed difference in seasonality for asthma controls (p=0.60).

247

Table 3. Clinical characteristics of asthma cases recruited during the

249 winter/spring (December through April) when RSV is typically circulating more

250 broadly in the community vs. the summer/fall (May through November).

	Winter/Spring	Summer/Fall	P-value
Ν	54	54	-
Age at Enrollment (mean)	12.0	11.6	0.53
Gender (% male)	53.7	51.9	1.0
BMI (mean)	26.0	24.9	0.47
Cotinine (NicAlert, mean)	0.85	1.1	0.13
Household Size at Enrollment	5.0	5.6	0.13
(mean)			
Undetected (IgG<10 IU/mL, N)	0	0	1.0
High IgG (IgG > 40 IU/mL, %)	37.0	85.2	4.3x10 ^{-7a}
RSV IgG (IU/mL, mean)	75.8	157	2.5x10 ^{-6a}
Hospitalizations from RSV (%)	18.5%	16.7%	1.0
RSV diagnosis (%)	33.3%	35.8%	0.84
Total Serum IgE [log (kU/L), mean]	5.3	5.1	0.53
% Eosinophils (mean)	4.9	5.1	0.80
CRP (log, mean)	0.038	0.38	0.26

^aStatistically significant following Bonferroni adjustment for 14 comparisons (p < 3.9x10⁻³).

252

253 Table 4. Results of multiple linear regression for total serum RSV IgG

concentrations.

	Estimate	Standard	Test	P-value
		Error	Statistic	
Asthma	29.8	14.4	2.07	0.0398 ^a
Household size	3.32	2.45	1.36	0.176
InBMI	-2.49	24.5	-0.102	0.919
Gender	-4.13	10.2	-0.407	0.684
Cotinine (NicAlert)	6.76	5.90	1.15	0.253
InCRP	-4.44	5.76	-0.770	0.442
age	-1.83	1.90	-0.959	0.339
RSV season	-9.47	15.5	-0.610	0.542
Total IgE	0.00108	0.00964	0.112	0.911
% Eosinophils	-3.42	1.61	-2.12	0.0350 ^a
Asthma x RSV season				
(interaction)	-68.0	23.2	-2.92	0.00373 ^b
°p<0.05				

255

256 ^bp<0.01

- Among 11 candidate variants selected from the literature to have potential effects
- on RSV infection, we identified a significant genetic association with an intronic variant
- in *IFNL4* (Interferon Lambda 4, Table 5).

Table 5. Results of genetic association at candidate variants with total serum RSV IgG concentration in 276

263 unrelated children with and without asthma. Tests for association were adjusted for asthma, age, and sex.

Gene	SNPs	Allele (A1/A2)	Freq A1	Beta A1	Test Statistic	P-value	Clinical Impact (references)
IFNG	rs2430561	T/A	0.14	-10.02	-0.9861	0.3249	RSV adult seroconversion [24,25]
TNF	rs1800629	A/G	0.038	-9.539	-0.4631	0.6437	Severe influenza, Experi-RSV [25,26]
IL-6	rs1800795	G/C	0.098	7.457	0.6311	0.5285	Experi-RSV, adults/children [24,25]
VDR	rs2228570	G/A	0.40	-7.002	-0.9072	0.3651	RSV bronchiolitis, infants [27,28]
MARCO	rs1801275	G/A	0.36	-3.211	-0.4033	0.6871	RSV and wheezing, Chilean children [29]
IFNL4	rs12979860	A/G	0.23	25.49	2.884	0.00425ª	Lower age at hospital admission for bronchiolitis [30]
	rs4986790	G/A	0.020	40.08	1.448	0.1487	RSV in high risk infants [31]; severe RSV [10,32,33]
IFNL3	rs2243639	A/G	0.30	2.226	0.2791	0.7804	RSV in Chilean infants [34]
ADRB2	rs1800888	A/G	0.0054	90	1.713	0.08782	Asthma following severe RSV bronchiolitis[11]
NOS1	rs76090928	A/G	0.0018	92.8	1.022	0.3078	Asthma following severe RSV bronchiolitis[11]

²⁶⁴ ^aStatistically significant following Bonferroni adjustment for 11 statistical comparisons.

266 **Discussion**

267

268	RSV and other viral infections at a young age have previously been associated
269	with the later development of asthma [8,35–38]. In a study of American Indian children
270	living in the Great Plain geographic area of rural South Dakota, we observed many
271	similarities in the clinical characteristics of children with asthma as with prior studies,
272	including increased BMI [39,40], increased hospitalizations or a diagnosis of RSV [41],
273	higher levels of total serum IgE [42,43], and higher % eosinophils [44,45].
274	In the current study, we measured immunological response to prior RSV
275	infection, and find children with asthma to have lower levels of serum RSV-specific IgG
276	as compared to those without asthma. Surprisingly, our finding is specific to children
277	with asthma who were recruited during the winter months, when RSV is thought to be
278	circulating more broadly in the community and within households. Our findings suggest
279	that children with asthma have a reduced or varying immunological response to RSV
280	infection during the winter months as compared to children without asthma, which is not
281	present during the summer months. Future longitudinal and prospective studies are
282	warranted to determine the timing of exposure as it relates to IgG immunological
283	response in children with and without asthma, and to determine any relationship with
284	acute vs. long-term clinical outcomes.

Very few studies have examined RSV-specific IgG antibody levels in the context of asthma and/or bronchial hyperreactivity for comparison to our current results. Backer et al examined RSV-specific IgG among a randomly selected group of children between

7 and 16 years of age, but found no association with bronchial hyper-responsiveness to 288 histamine challenge [46]. In another study among 100 children less than 2 years of age 289 hospitalized for wheezing and followed for a median of 6 years, RSV-specific IgG 290 increased with age, but was not associated with asthma at any age [47]. In our cross-291 sectional study, we found no significant association between RSV IgG concentration 292 293 and age in either our single or multi-variate analysis, however we did not perform any longitudinal measurements within an individual. Although we are unaware of any recent 294 findings to date, the INSPIRE longitudinal study of RSV serology among nearly 2,000 295 infants may provide further information as to whether immunological response to RSV 296 infection is predictive of asthma or varies by season or age [48]. 297

Lower RSV-specific IgG concentrations in asthma cases during the winter 298 months when RSV is thought to be circulating more broadly in the community was an 299 unanticipated finding (Fig 1). IgG antibodies typically peak within 3-4 weeks following 300 RSV infection and gradually decline over the next few months [49,50]. Thus, we 301 302 expected RSV IgG concentrations to be higher during times of recurring exposure during the winter months for both asthma cases and controls. While the seasonality of 303 304 RSV infection is well accepted [50,51], we were unable to locate any independent 305 cohort surveillance information or cross-sectional serology surveys that recorded seasonal timing of collection for comparison to our results. Thus, further efforts to 306 validate our findings and identify potential causal factors driving the observed interaction 307 between asthma and RSV season on IgG concentrations requires additional study. 308

Parents of children with asthma were more likely to report their child had been
 previously diagnosed with RSV, and we observed a non-significant trend towards

increased rate of hospitalization due to RSV. While we do not have information on the 311 312 clinical course of RSV infection in our study participants beyond self-report, we 313 identified a shared genetic association that may provide additional insight as to whether RSV-specific IgG concentrations are of any clinical relevance. The IFNL4 variant we 314 found associated with RSV-specific lgG is a member of the interferon lambda family. 315 316 which is known to be involved in the immune response to viral infection. We identified this as a candidate variant from Scagnolari et al [30], who found that individuals with the 317 AA genotype had a lower age at hospital admission due to RSV infection as compared 318 to infants carrying the GG/GA genotypes. In our study, Individuals with the AA genotype 319 had significantly higher levels of RSV-specific IgG as compared to individuals with the 320 GG genotype (Fig 2). Although this requires validation, our findings in combination with 321 Scagnolari et al. [30] suggest that individuals with two copies of the minor allele (AA 322 genotype) have a heightened immunological response to RSV infection that may lead to 323 324 increased hospitalization with RSV at a younger age. Prior studies have also found the A allele associated with clinical presentation of allergic disease, including increased 325 rates of asthma, atopic dermatitis, and IgE-mediated food allergy for both the AG and 326 327 AA genotypes [52], but with a lower incidence of COVID19 [53]. Lastly, this variant has been associated with varying response to pegylated interferon-alpha and ribavirin 328 329 treatment [54,55] and spontaneous clearance of hepatitis C infection [56,57], suggesting 330 the influence on viral infection is not exclusive to respiratory diseases.

331

333	Figure 2. Median levels of RSV IgG concentration by genotype at rs12979860, an
334	intronic variant in <i>IFNL4</i> that is associated with RSV IgG concentration in
335	individuals with and without asthma (Table 6, p=0.0043). Individuals with two
336	copies of the minor A allele (AA genotype) have significantly higher levels of RSV
337	IgG as compared to individuals with two copies of the major G allele (GG
338	genotype) (t-test, p=0.01).

339

We identified elevated total IgE concentrations (geometric mean 111.1 IU/ml) in 340 both asthma cases and controls overall, similar to that reported in Alaskan Native 341 children (geometric mean 122.1 kU/L) and in comparison to the Tucson Childhood 342 Respiratory Study (geometric mean 36.3 kU/L) [58]. A Korean cohort of children 343 between 12-13 years of age found a geometric mean total IgE of 90.6 kU/L and a 95 344 percentile of 991 kU/L [59]. High levels of IgE are consistent with a predominant 345 inflammatory asthma phenotype in our study, and similar to that reported by Redding et 346 al. in Alaskan Native children [58]. Elevated levels of total IgE suggest tendencies 347 toward immune hyperreactivity and asthma at the community level, in accordance with 348 reports of increased asthma prevalence in various other Indigenous communities 349 [60,61]. Consistent with there being a tradeoff in IgE vs. IgG production, and preferential 350 351 IqE production in Th2 cytokine environment [62,63], we indeed find lower levels of total IgE in individuals with high RSV-specific IgG concentrations as compared to individuals 352 with low RSV concentrations (Table 2). However, total IgE was not predictive of RSV 353 354 IgG in our multivariable model that included asthma status (Table 4), and may indicate a

confounding correlation between asthma, % eosinophils, and serum total IgE on
 immunological response to RSV that requires further study.

We find children with high RSV IgG concentration tended to live in larger 357 358 households, and had higher levels of cotinine levels indicating increased exposure to second-hand tobacco smoke. These observations are consistent with prior studies [51] 359 that identified household crowding as a risk factor for RSV [64,65], including one study 360 among Alaskan Native children [66]. Prior studies have also found a relationship 361 between cotinine levels and increased risk of bronchiolitis and other complications of 362 RSV infection [67-69]. While we could not examine the effect of household size and 363 cotinine levels on clinical outcomes of RSV infection directly, our observation of higher 364 cotinine levels in children with high RSV IgG concentration is important given that 365 tobacco use and exposure is a serious public health concern in this community [70]. 366

367

368 Conclusion

369

In this study we report high RSV-specific IgG concentrations among a case-control
study of asthma in American Indian children living in the Great Plains geographical area
of the U.S. RSV-specific IgG concentrations were lower in children with asthma as
compared to children without asthma during the winter months when RSV was likely
circulating at higher levels in the community. Factors contributing to this observation
include both genetic and environmental risk factors that require additional study.

376 Acknowledgements

377

- 378 We thank the study participants, Indian Health Service facilities, the Collaborative
- 379 Research Center for American Indian Health, the Colorado Anschutz Research
- 380 Genetics Organization (CARGO lab), and participating tribal community for their
- 381 extraordinary cooperation and involvement, which has been critical to the success of
- this investigation. The views expressed in this paper are those of the authors and do not
- necessarily reflect those of the Indian Health Service. Funding was provided by the
- National Institute of Minority Health and Health Disparities, grant U54 MD008164.

385

386

388 References

- 1. Smyth RL. Openshaw PJ. Bronchiolitis Lancet. 2006;368: 312–322.
- Dayan PS, Roskind CG, Levine DA, Kuppermann N. Controversies in the
 management of children with bronchiolitis. Clin Pediatr Emerg Med. 2004;5: 41–53.
- Simoes EAF, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J. 2003;22: S13–S20.
- Mansbach JM, Emond JA, Camargo CA Jr. Bronchiolitis in US emergency
 departments 1992 to 2000: epidemiology and practice variation. Pediatr Emerg
 Care. 2005;21: 242–247.
- Holman RC, Curns AT, Cheek JE, Bresee JS, Singleton RJ, Carver K, et al.
 Respiratory syncytial virus hospitalizations among American Indian and Alaska
 Native infants and the general United States infant population. Pediatrics. 2004;114:
 e437-44.
- 402 6. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F,
 403 et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and
 404 allergy at age 13. Am J Respir Crit Care Med. 2005;171: 137–141.
- 405 7. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al.
 406 Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13
 407 years. Lancet. 1999;354: 541–545.
- 408 8. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM.
 409 Hospitalization for RSV bronchiolitis before 12 months of age and subsequent
 410 asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy
 411 Immunol. 2005;16: 386–392.
- 412 9. Gómez R, Colás C, Sebastián A, Arribas J. Respiratory repercussions in adults with
 413 a history of infantile bronchiolitis. Ann Allergy Asthma Immunol. 2004;93: 447–451.
- Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, et al. Association between
 common Toll-like receptor 4 mutations and severe respiratory syncytial virus
 disease. J Infect Dis. 2004;189: 2057–2063.
- 11. Torgerson DG, Giri T, Druley TE, Zheng J, Huntsman S, Seibold MA, et al. Pooled
 sequencing of candidate genes implicates rare variants in the development of
 asthma following severe RSV bronchiolitis in infancy. PLoS One. 2015;10:
 e0142649.
- 421 12. Gentile DA, Doyle WJ, Zeevi A, Howe-Adams J, Kapadia S, Trecki J, et al. Cytokine
 422 gene polymorphisms moderate illness severity in infants with respiratory syncytial
 423 virus infection. Hum Immunol. 2003;64: 338–344.

Hull J, Rowlands K, Lockhart E, Moore C, Sharland M, Kwiatkowski D. Variants of
 the chemokine receptor CCR5 are associated with severe bronchiolitis caused by
 respiratory syncytial virus. J Infect Dis. 2003;188: 904–907.

- 427 14. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al.
 428 Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J
 429 Allergy Clin Immunol. 2012;130: 91-100.e3.
- 430 15. Agius G, Dindinaud G, Biggar RJ, Peyre R, Vaillant V, Ranger S, et al. An epidemic
 431 of respiratory syncytial virus in elderly people: clinical and serological findings. J
 432 Med Virol. 1990;30: 117–127.
- 433 16. Falsey AR, Walsh EE, Looney RJ, Kolassa JE, Formica MA, Criddle MC, et al.
 434 Comparison of respiratory syncytial virus humoral immunity and response to
 435 infection in young and elderly adults. J Med Virol. 1999;59: 221–226.
- 436 17. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and
 437 human metapneumovirus by reverse transcription polymerase chain reaction in
 438 adults with and without respiratory illness. J Clin Virol. 2006;35: 46–50.
- 18. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366:
 15021.
- 441 19. Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, et al.
 442 The epidemiology of medically attended respiratory syncytial virus in older adults in
 443 the United States: A systematic review. PLoS One. 2017;12: e0182321.
- Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an
 under-recognized problem. Drugs Aging. 2015;32: 261–269.
- 21. Schmidt H, Das A, Nam H, Yang A, Ison MG. Epidemiology and outcomes of
 hospitalized adults with respiratory syncytial virus: A 6-year retrospective study.
 Influenza Other Respi Viruses. 2019;13: 331–338.
- 449 22. Best LG, O'Leary RA, O'Leary MA, Yracheta JM. Humoral immune factors and
 450 asthma among American Indian children: a case-control study. BMC Pulm Med.
 451 2016;16: 93.
- 452 23. R Core Team. R: A language and environment for statistical computing. R
 453 Foundation for Statistical Computing, Vienna, Austria. 2018. Available:
 454 https://www.R-project.org/
- 455 24. Doyle WJ, Casselbrant ML, Li-Korotky H-S, Doyle APC, Lo C-Y, Turner R, et al.
 456 The interleukin 6 -174 C/C genotype predicts greater rhinovirus illness. J Infect Dis.
 457 2010;201: 199–206.
- 458 25. Gentile DA, Doyle WJ, Zeevi A, Piltcher O, Skoner DP. Cytokine gene
 459 polymorphisms moderate responses to respiratory syncytial virus in adults. Hum
 460 Immunol. 2003;64: 93–98.

461 26. Martinez-Ocaña J, Olivo-Diaz A, Salazar-Dominguez T, Reyes-Gordillo J, Tapia 462 Aquino C, Martínez-Hernández F, et al. Plasma cytokine levels and cytokine gene
 463 polymorphisms in Mexican patients during the influenza pandemic A(H1N1)pdm09.
 464 J Clin Virol. 2013;58: 108–113.

- 465 27. McNally JD, Sampson M, Matheson LA, Hutton B, Little J. Vitamin D receptor
 466 (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta467 analysis. Pediatr Pulmonol. 2014;49: 790–799.
- 468 28. Laplana M, Royo JL, Fibla J. Vitamin D Receptor polymorphisms and risk of
 469 enveloped virus infection: A meta-analysis. Gene. 2018;678: 384–394.
- 470 29. Tapia LI, Ampuero S, Palomino MA, Luchsinger V, Aguilar N, Ayarza E, et al.
 471 Respiratory syncytial virus infection and recurrent wheezing in Chilean infants: a
 472 genetic background? Infect Genet Evol. 2013;16: 54–61.
- 30. Scagnolari C, Midulla F, Riva E, Monteleone K, Solimini A, Bonci E, et al.
 Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering
 from bronchiolitis. Virus Res. 2012;165: 236–240.
- 476 31. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, Boukhvalova MS, et al.
 477 Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus
 478 infection in high-risk infants and young children. J Immunol. 2007;179: 3171–3177.
- 32. Tulic MK, Hurrelbrink RJ, Prêle CM, Laing IA, Upham JW, Le Souef P, et al. TLR4
 polymorphisms mediate impaired responses to respiratory syncytial virus and
 lipopolysaccharide. J Immunol. 2007;179: 132–140.
- 33. Zhou J, Zhang X, Liu S, Wang Z, Chen Q, Wu Y, et al. Genetic association of TLR4
 Asp299Gly, TLR4 Thr399lle, and CD14 C-159T polymorphisms with the risk of
 severe RSV infection: a meta-analysis. Influenza Other Respi Viruses. 2016;10:
 224–233.
- 486 34. Ampuero S, Luchsinger V, Tapia L, Palomino MA, Larrañaga CE. SP-A1, SP-A2
 487 and SP-D gene polymorphisms in severe acute respiratory syncytial infection in
 488 Chilean infants. Infect Genet Evol. 2011;11: 1368–1377.
- 35. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson
 Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003;111:
 661–75; quiz 676.
- 36. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee W-M, et al.
 Evidence for a causal relationship between allergic sensitization and rhinovirus
 wheezing in early life. Am J Respir Crit Care Med. 2012;185: 281–285.
- 495 37. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary
 496 prevention of asthma. Reviewing the evidence for early-life respiratory viral
 497 infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit
 498 Care Med. 2015;191: 34–44.

38. Lee KK, Hegele RG, Manfreda J, Wooldrage K, Becker AB, Ferguson AC, et al.
Relationship of early childhood viral exposures to respiratory symptoms, onset of
possible asthma and atopy in high risk children: the Canadian Asthma Primary
Prevention Study. Pediatr Pulmonol. 2007;42: 290–297.

- 39. Noonan CW, Brown BD, Bentley B, Conway K, Corcoran M, FourStar K, et al.
 Variability in childhood asthma and body mass index across Northern Plains
 American Indian communities. J Asthma. 2010;47: 496–500.
- 40. Dixon AE, Holguin F. Diet and metabolism in the evolution of asthma and obesity.
 Clin Chest Med. 2019;40: 97–106.
- 41. Anderson J, Do LAH, Wurzel D, Quan Toh Z, Mulholland K, Pellicci DG, et al.
 Severe respiratory syncytial virus disease in preterm infants: a case of innate
 immaturity. Thorax. 2021; thoraxjnl-2020-216291.
- 42. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184:
 2521–2522.
- 43. Lee Y, Quoc QL, Park HS. Biomarkers for severe asthma: Lessons from
 longitudinal cohort studies. Allergy Asthma Immunol Res. 2021;13: 375–389.
- 44. Karakoc F, Remes ST, Martinez FD, Wright AL. The association between persistent
 eosinophilia and asthma in childhood is independent of atopic status. Clin Exp
 Allergy. 2002;32: 51–56.
- 45. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US
 perspective. J Asthma Allergy. 2014;7: 53–65.
- 46. Backer V, Ulrik CS, Bach-Mortensen N, Glikmann G, Mordhorst CH. Relationship
 between viral antibodies and bronchial hyperresponsiveness in 495 unselected
 children and adolescents. Allergy. 1993;48: 240–247.
- 47. Kotaniemi-Syrjänen A, Laatikainen A, Waris M, Reijonen TM, Vainionpää R, Korppi
 M. Respiratory syncytial virus infection in children hospitalized for wheezing: virus specific studies from infancy to preschool years. Acta Paediatr. 2005;94: 159–165.
- 48. Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, et al.
 Objectives, design and enrollment results from the Infant Susceptibility to
 Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). BMC
 Pulm Med. 2015;15: 45.
- 49. Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL. The antibody
 response to primary and secondary infection with respiratory syncytial virus: kinetics
 of class-specific responses. J Pediatr. 1980;96: 808–813.
- 533 50. Kutsaya A, Teros-Jaakkola T, Kakkola L, Toivonen L, Peltola V, Waris M, et al.
 534 Prospective clinical and serological follow-up in early childhood reveals a high rate

- of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life. Epidemiol Infect. 2016;144: 1622–1633.
- 537 51. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial 538 virus lower respiratory tract disease. J Pediatr. 2003;143: S118-26.
- 539 52. Chinnaswamy S, Wardzynska A, Pawelczyk M, Makowska J, Skaaby T, Mercader
 540 JM, et al. A functional IFN-λ4-generating DNA polymorphism could protect older
 541 asthmatic women from aeroallergen sensitization and associate with clinical
 542 features of asthma. Sci Rep. 2017;7: 10500.
- 53. Agwa SHA, Kamel MM, Elghazaly H, Abd Elsamee AM, Hafez H, Girgis SA, et al.
 Association between interferon-lambda-3 rs12979860, TLL1 rs17047200 and DDR1
 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2
 patients. Genes (Basel). 2021;12: 830.
- 547 54. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B
 548 is associated with response to chronic hepatitis C interferon-alpha and ribavirin
 549 therapy. Nat Genet. 2009;41: 1100–1104.
- 55. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al.
 Genome-wide association of IL28B with response to pegylated interferon-alpha and
 ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41: 1105–1109.
- 553 56. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-554 wide association study of spontaneous resolution of hepatitis C virus infection: data 555 from multiple cohorts. Ann Intern Med. 2013;158: 235–245.
- 556 57. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic
 557 variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature.
 558 2009;461: 399–401.
- 559 58. Redding GJ, Singleton RJ, DeMain J, Bulkow LR, Martinez P, Lewis TC, et al.
 560 Relationship between IgE and specific aeroallergen sensitivity in Alaskan native
 561 children. Ann Allergy Asthma Immunol. 2006;97: 209–215.
- 562 59. Kim HY, Choi J, Ahn K, Hahm MI, Lee SY, Kim WK, et al. Reference values and
 563 utility of serum total immunoglobulin E for predicting atopy and allergic diseases in
 564 Korean schoolchildren. J Korean Med Sci. 2017;32: 803–809.
- 60. Upson DJ. Asthma in Navajo children: Striving for health equity. Annals of the
 American Thoracic Society. American Thoracic Society; 2018. pp. 671–674.
- 61. Clark D, Gollub R, Green WF, Harvey N, Murphy SJ, Samet JM. Asthma in Jemez
 Pueblo schoolchildren. Am J Respir Crit Care Med. 1995;151: 1625–1627.
- 62. Wesemann DR, Magee JM, Boboila C, Calado DP, Gallagher MP, Portuguese AJ,
 et al. Immature B cells preferentially switch to IgE with increased direct Sμ to Sε
 recombination. J Exp Med. 2011;208: 2733–2746.

572 63. Scott-Taylor TH, Axinia S-C, Amin S, Pettengell R. Immunoglobulin G; structure and
 573 functional implications of different subclass modifications in initiation and resolution
 574 of allergy. Immun Inflamm Dis. 2018;6: 13–33.

- 64. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk
 factors for respiratory syncytial virus-associated lower respiratory illnesses in the
 first year of life. Am J Epidemiol. 1991;133: 1135–1151.
- 65. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for
 respiratory syncytial virus infection in premature infants born during two consecutive
 seasons. Pediatr Infect Dis J. 2001;20: 874–879.
- 66. Bulkow LR, Singleton RJ, Karron RA, Harrison LH, Alaska RSV Study Group. Risk
 factors for severe respiratory syncytial virus infection among Alaska native children.
 Pediatrics. 2002;109: 210–216.
- 67. Gürkan F, Kiral A, Dağli E, Karakoç F. The effect of passive smoking on the
 development of respiratory syncytial virus bronchiolitis. Eur J Epidemiol. 2000;16:
 465–468.
- 587 68. Sritippayawan S, Prapphal N, Wong P, Tosukhowong P, Samransamruajkit R,
 588 Deerojanawong J. Environmental tobacco smoke exposure and respiratory
 589 syncytial virus infection in young children hospitalized with acute lower respiratory
 590 tract infection. J Med Assoc Thai. 2006;89: 2097–2103.
- 69. Maedel C, Kainz K, Frischer T, Reinweber M, Zacharasiewicz A. Increased severity
 of respiratory syncytial virus airway infection due to passive smoke exposure.
 Pediatr Pulmonol. 2018;53: 1299–1306.
- 70. O'Donald ER, Miller CP, O'Leary R, Ong J, Pacheco B, Foos K, et al. Active
 smoking, secondhand smoke exposure and serum cotinine levels among Cheyenne
 River Sioux communities in context of a Tribal Public Health Policy. Tob Control.
 2020;29: 570–576.
- 598
- 599
- 600

Supporting Information Captions

- 603 S1 Fig. Boxplot showing the distribution of Measles, Pertussis, and Tetanus titers
- 604 stratified by high (IgG>10 IU/mL, N=27) vs. low RSV IgG (IgG<10 IU/mL, N=16).





RSV IgG Concentration (U/mL)

medRxiv preprint doi: https://doi.org/10.1101/2021.08.17.21262198; this version posted August 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .





Pertussis